Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Enfortumab Vedotin Gets FDA Priority Review for Urothelial Cancer: Astellas/Seattle Genetics
September 18, 2019
- Mitsubishi Tanabe Grants Daiichi Sankyo Commercialization Rights for Edaravone in Brazil
September 18, 2019
- Astellas Ventures into Medical Device Arena with Iota Deal
September 17, 2019
- Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
- Eisai, Biogen Drop PIII Studies for Elenbecestat
September 17, 2019
- ViiV Files Anti-HIV Drug Combo Dovato in Japan
September 17, 2019
- Promotion Push Continues for Daiichi Sankyo’s Pain Drug Tarlige in July: Impact Track
September 13, 2019
- Takeda, PwC to Develop App for Crohn’s Disease
September 13, 2019
- MSD Files HIV-1 Drug Doravirine in Japan
September 13, 2019
- Chugai’s Satralizumab Hits Primary Target in PIII Study
September 13, 2019
- IT Startup Activaid Offers Clinical Trial Matching Service for IBD Patients through App
September 12, 2019
- Opdivo Showed 5-Year Survival Rates of 13.4% in 2nd-Line NSCLC in PIII Studies
September 12, 2019
- Fujifilm Rolls Out iPS Cell-Derived Small Intestinal Cell in Japan for Use in Assessing Drug Absorption
September 12, 2019
- Full Approval in Japan Will Be 1st Goal for Collategene: AnGes Chief
September 11, 2019
- Vital-Net Carving Out New Businesses in Regenerative Medicine, Robotics
September 11, 2019
- Keytruda Filed for Esophageal Cancer in Japan
September 11, 2019
- Wakamoto Casts Off Glaucoma Hopeful on Safety Worries
September 11, 2019
- Daiichi Sankyo Presents Updated PI Data of ADCs DS-1062, U3-1402 for NSCLC
September 11, 2019
- 1st RNAi Therapy Onpattro Makes Japan Debut
September 10, 2019
- Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…